Microinjection of neurotensin (NT) into the rostral ventromedial medulla (RVM) produces dose-dependent antinociception. Here we show that antinociception produced by intra-RVM microinjection of neurotensin (NT) or the selective NT receptor subtype 1 (NTR1) agonist PD149163 can be partially blocked by intrathecal (i.t.) yohimbine, an a2-adrenoceptor antagonist and by methysergide, a serotonin receptor antagonist. Antinociception produced by the NTR2 agonist beta-lactotensin (b-LT) is blocked by intrathecal (i.t.) yohimbine, but not by methysergide i.t. It is not known which noradrenergic cell group is involved in this newly identified noradrenergic component of NTR-mediated antinociception.
Introduction
Microinjection of neurotensin (NT) into the rostral ventromedial medulla (RVM) has biphasic effects on nociception; facilitation is produced by low doses (0.03 pmol-0.03 nmol) and inhibition by greater doses (1.3-30 nmol) (Behbehani and Pert, 1984; Fang et al., 1987; Urban and Smith, 1993; Urban et al., 1996 Urban et al., , 1999 Sarhan et al., 1997; Holmes et al., 1999 , but see Neubert et al., 2004 . It has been shown that the facilitatory effect of intra-RVM NT is mediated through release of cholecystokinin in the spinal dorsal horn (Urban et al., 1996) , while at least part of the antinociceptive effect is mediated through activation of NTR1 and release of serotonin in the spinal dorsal horn (Buhler et al., 2005) . It has been suggested that an imbalance of facilitation and inhibition may play a role in some chronic pain states (Urban and Gebhart, 1999; Porreca et al., 2002) .
Of the three cloned NT binding proteins, NTR1 and NTR2 are G-protein coupled receptors (Tanaka et al., 1990; Chalon et al., 1996) , while the NTR3 (gp95/sortilin) induces phosphorylation of Erk1/2 and Akt kinases and induces the expression of several chemokines/cytokines, including TNFa and IL-1b (Trudeau, 2000) . Both NTR1 and NTR2 are expressed in the RVM (Sarret et al., 2003; Buhler et al., 2005) and several studies have shown that NTR1 is involved in antinociception (Wustrow et al., 1995; Urban and Gebhart, 1997; Smith et al., 1997; Buhler et al., 2005) . There is, however, 
